{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0333","statisticalComment":"Strata: intolerance to imatinib treatment","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.6","upperLimit":"31.2","value":"23.9"},{"groupId":"OG001","lowerLimit":"9.6","upperLimit":"21.0","value":"14.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"163"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"ORR was defined as the proportion of patients with confirmed complete response (CR) + confirmed partial response (PR) based on independent radiologic review using modified RECIST (mRECIST) criteria as best overall response. Per mRECIST 1.1 criteria, complete response is defined as disappearance of all target lesions; partial response is defined as \\>=30% decrease in the sum of the longest diameter of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Ripretinib (150 mg) once a day continuous dosing for 6-week (42 days) cycles","id":"OG000","title":"Ripretinib"},{"description":"Sunitinib (50 mg) once a day in 6-week (42 days) cycles with 4 weeks continuous dosing followed by 2 week break.","id":"OG001","title":"Sunitinib"}],"paramType":"NUMBER","populationDescription":"The KIT Exon 11 Intent to Treat (ITT) Population is defined as all patients who are designated as having a mutation in KIT Exon 11 at the time of randomization. Patients in this population will be analyzed according to the treatment they were scheduled to receive.","reportingStatus":"POSTED","timeFrame":"From confirmed CR or PR to disease progression (up to 1.74 years)","title":"Objective Response Rate (ORR) in the KIT Exon 11 Intent to Treat (ITT) Population Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}